Therapeutic effect of Gliflozins in Nonalcoholic Hepatic Steatosis
DOI:
https://doi.org/10.56294/piii2023149Keywords:
Gliflozins, fatty liver, Diabetes, Non-alcoholic fatty liverAbstract
Background: The disease called non-alcoholic fatty liver (NAFLD its acronym in English) is the most common chronic liver disease worldwide, its general prevalence is high, on average 25%. One study showed that the prevalence of NAFLD is increasing with approximately 3.6 million cases each year. Metabolic stress is closely related to insulin resistance (IR). It is frequently associated with metabolic syndromes such as obesity and dyslipidemia.
Material and methods: Systematic review with qualitative and quantitative database of the platform PUBMED. The articles were downloaded from the PUBMED platform and the Zotero program was used to make
proper citations and references. Articles that include adult patients of both biological sexes will be analyzed
References
Nagoya T, Kamimura K, Goto R, Shinagawa-Kobayashi Y, Niwa Y, Kimura A, et al. Inhibition of sodiumglucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitisrelated kidney disease. FEBS Open Bio. diciembre de 2019;9(12):2016-24.
Machida T, Obara T, Miyazaki M, Inoue J, Mano N. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Annals of Hepatology. 1 de julio de 2022;27(4):100699.
ElMahdy MKh, Helal MG, Ebrahim TM. Potential antiinflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of
TNF-α, IL-1β, and IL-18 in rat liver. International Immunopharmacology. 1 de septiembre de 2020;86:106730.
Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. octubre de 2021;54(8):1013-25.
Xu B, Li S, Kang B, Zhou J. The current role of sodiumglucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology. 25 de mayo de 2022;21(1):83.
Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte. 3 de abril de 2018;7(2):121-8.
Nagoya T, Kamimura K, Goto R, Shinagawa-Kobayashi Y, Niwa Y, Kimura A, et al. Inhibition of sodiumglucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitisrelated kidney disease. FEBS Open Bio. 2019;9(12):2016-24.
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: CoSponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 1 de mayo de 2022;28(5):528-62.
White JR. Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus: A Review of the Evidence. Ann Pharmacother. 1 de mayo de;49(5):582-98.
Luo J, Sun P, Wang Y, Chen Y, Niu Y, Ding Y, et al. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. European Journal of Pharmacology. 15 de septiembre de;907:174304.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Antonella Maribel Salto, Marcelo Adrián Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
